von Heesen A, Nilges K, Radosa J, et al. Incidence of skeletal-related events in patients suffering of bone metastasis from breast cancer treated with bisphosphonates or denosumab. SABCS 2017, P1-16-05.
Tucatinib verlengt mediane overleving met 5,5 maand in finale analyse HER2CLIMB-studie
mrt 2022 | Borstkanker